PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION, AND COMBINED FORMULATION KIT FOR PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, ORAL ANTIVIRAL AGENT AND THERAPEUTIC VACCINE INCLUDING LIPOPEPTIDE AND POLY(I:C) ADJUVANT

The present invention relates to a pharmaceutical composition, a pharmaceutical combined formulation, and a combined formulation kit, each comprising, as active ingredients, an oral antiviral agent and a therapeutic vaccine including a lipopeptide and a poly(I:C) adjuvant. When the pharmaceutical composition, the pharmaceutical combined agent, and the combined formulation kit are administered/used in hepatitis B patients, a remarkable synergy occurs in terms of therapeutic index for chronic hepatitis B, compared to patients who have undergone standard therapy including the administration of conventional antiviral agents, exhibiting the possibility of completely curing the disease.